Company Focus
AstraZeneca
Latest AstraZeneca News
Pharmaceutical
The US eosinophilic esophagitis (EoE) market is projected to grow from $202 million in 2020 to $1.19 billion in 2030, registering a compound annual growth rate (CAGR) of 19.4%. 26 August 2025
Related News
Insights
Company Spotlight
A specialty pharmaceutical company engaged in the discovery, development, manufacturing and marketing of branded prescription and nonprescription products in more than 60 countries on five continents.
Latest News & Features of interest to AstraZeneca
Pharmaceutical
Weight loss medication provider CheqUp has announced that it will maintain the current prices of Mounjaro (tirzepatide) 2.5mg at £149 ($202) and 5mg at £169 from Monday, following recent price increases by Eli Lilly. 1 September 2025
Pharmaceutical
Cytokinetics (Nasdaq: CYTK) has taken a major step forward with aficamten, its experimental therapy for obstructive hypertrophic cardiomyopathy. In a Phase III trial unveiled at the European Society of Cardiology congress and published in the New England Journal of Medicine, aficamten outperformed metoprolol, the beta blocker long used as the standard treatment. 1 September 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has approved French pharma major Sanofi’s Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. 1 September 2025
Pharmaceutical
Danish pharma major Novo Nordisk on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. 1 September 2025
Biotechnology
Significant research news last week included Netherlands-based argenx, release of positive Phase III results for its myasthenia gravis (gMG) candidate Vyvgart, and Regeneron announcement of Phase III data on its cemdisiran and pozelimab, also for the treatment gMG. On the regulatory front, Amgen won US Food and Drug Administration (FDA) approval for its Repatha for the extended indication for patients at risk of major cardiovascular events. Also, of note, the FDA backed biomarkers for the development of metabolic dysfunction-associated steatohepatitis (MASH) clinical trials. 31 August 2025
Pharmaceutical
US pharma giant Merck & Co today announced results evaluating Verquvo (vericiguat) in adult patients with stable chronic heart failure and reduced ejection fraction (HFrEF). 30 August 2025
Pharmaceutical
ITF Therapeutics, the US affiliate of privately-held Italian firm Italfarmaco, has announced publication of positive long-term safety and efficacy data for Duvyzat (givinostat) in Duchenne muscular dystrophy (DMD) from the company’s open-label extensions of its Phase II and Phase III (EPIDYS) trials. 29 August 2025
Pharmaceutical
Fosun Pharma has inked a deal with fellow China-based Accro Bioscience that grants it exclusive rights to develop, manufacture, and commercialize its independently developed, highly selective TYK2/JAK1 inhibitor in Greater China (including Chinese Mainland, Hong Kong SAR, and Macau SAR). 29 August 2025
Pharmaceutical
Santhera Pharmaceuticals, a Swiss specialty pharma company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases, has signed a deal with India’s Ikris Pharma Network. 29 August 2025
Pharmaceutical
US pharma major Eli Lilly has temporarily halted UK orders of its weight-loss drug Mounjaro (tirzepatide), Reuters reports. 29 August 2025
Latest In Brief for AstraZeneca
Pharmaceutical
Shares in Biohaven moved up about 7% on Friday after the company provided an update with respect to its New Drug Application (NDA) for troriluzole for the treatment of adult patients with spinocerebellar ataxia (SCA), in a filing with the Securities and Exchange Commission (SEC). 26 August 2025
Latest Related Ones To Watch News
MannKind Corporation yesterday signed a definitive agreement to acquire fellow USA-based scPharmaceuticals, with the news seeing the latter’s shares close up 13.8% at $5.52. 26 August 2025
21 August 2025
19 August 2025
12 August 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze